Table 2 Associations between the differential gene expression score and colorectal cancer-specific mortality
From: Improved survival among colon cancer patients with increased differentially expressed pathways
Pathways | T1 HR 1 (referent) | T2 HR 1 | (95% CI) | T3 HR 1 | (95% CI) |
|---|---|---|---|---|---|
Cell Cycle Control of Chromosomal Replication | 1.00 | 0.36 | (0.17, 0.77) | 0.37 | (0.16, 0.87) |
Estrogen-mediated S-phase Entry | 1.00 | 0.38 | (0.18, 0.81) | 0.35 | (0.15, 0.81) |
Thyroid Hormone Metabolism II | 1.00 | 1.26 | (0.57, 2.78) | 1.60 | (0.71, 3.63) |
Hepatic Fibrosis / Hepatic Stellate Cell Activation | 1.00 | 0.73 | (0.33, 1.58) | 0.75 | (0.34, 1.65) |
Cell Cycle: G1/S Checkpoint Regulation | 1.00 | 0.39 | (0.19, 0.81) | 0.44 | (0.18, 1.07) |
Melatonin Degradation I | 1.00 | 1.58 | (0.71, 3.54) | 1.44 | (0.66, 3.12) |
Serotonin Degradation | 1.00 | 1.29 | (0.58, 2.87) | 1.48 | (0.68, 3.23) |
Superpathway of Melatonin Degradation | 1.00 | 1.58 | (0.71, 3.54) | 1.44 | (0.66, 3.12) |
Cyclins and Cell Cycle Regulation | 1.00 | 0.41 | (0.20, 0.87) | 0.28 | (0.12, 0.67) |
Cell Cycle: G2/M DNA Damage Checkpoint Regulation | 1.00 | 0.35 | (0.16, 0.75) | 0.34 | (0.15, 0.78) |
GADD45 Signaling | 1.00 | 0.34 | (0.15, 0.74) | 0.36 | (0.15, 0.82) |
Mismatch Repair in Eukaryotes | 1.00 | 0.51 | (0.23, 1.10) | 0.38 | (0.17, 0.88) |
Mitotic Roles of Polo-Like Kinase | 1.00 | 0.54 | (0.26,1.16) | 0.43 | (0.19, 1.01) |
Agranulocyte Adhesion and Diapedesis | 1.00 | 0.68 | (0.31, 1.49) | 0.59 | (0.27, 1.32) |
Hereditary Breast Cancer Signaling | 1.00 | 0.40 | (0.19, 0.85) | 0.33 | (0.14, 0.78) |
Granulocyte Adhesion and Diapedesis | 1.00 | 0.73 | (0.34, 1.59) | 0.54 | (0.24, 1.23) |
Nicotine Degradation III | 1.00 | 1.59 | (0.73, 3.47) | 1.59 | (0.68, 3.70) |
Nicotine Degradation II | 1.00 | 1.81 | (0.81, 4.05) | 1.93 | (0.86, 4.34) |
TP53 Signaling | 1.00 | 0.39 | (0.18, 0.84) | 0.34 | (0.14, 0.78) |
Axonal Guidance Signaling | 1.00 | 0.49 | (0.21, 1.11) | 0.86 | (0.41, 1.81) |
Aryl Hydrocarbon Receptor Signaling | 1.00 | 0.42 | (0.20, 0.92) | 0.36 | (0.16, 0.80) |
Role of BRCA1 in DNA Damage Response | 1.00 | 0.46 | (0.22, 0.97) | 0.33 | (0.14, 0.81) |
ATM Signaling | 1.00 | 0.43 | (0.20, 0.92) | 0.34 | (0.15, 0.80) |
Complement System | 1.00 | 1.28 | (0.56, 2.93) | 1.01 | (0.41, 2.51) |
Superpathway of Serine and Glycine Biosynthesis I | 1.00 | 0.43 | (0.18, 1.03) | 0.30 | (0.13, 0.69) |
Atherosclerosis Signaling | 1.00 | 0.70 | (0.32, 1.56) | 0.88 | (0.41, 1.87) |
Role of CHK Proteins in Cell Cycle Checkpoint Control | 1.00 | 0.44 | (0.21, 0.90) | 0.35 | (0.14, 0.86) |
RAN Signaling | 1.00 | 0.36 | (0.16,0.81) | 0.39 | (0.17, 0.86) |
Purine Nucleotides De Novo Biosynthesis II | 1.00 | 0.36 | (0.17, 0.77) | 0.26 | (0.10, 0.66) |
Eicosanoid Signaling | 1.00 | 0.97 | (0.44,2.14) | 0.91 | (0.40, 2.08) |
Wnt/ß-catenin Signaling | 1.00 | 0.38 | (0.17, 0.85) | 0.44 | (0.20, 0.99) |